Top

International Journal of Clinical Oncology

Published in:

01-06-2010 | Case Report

Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing

Authors: Takeru Wakatsuki, Atsushi Irisawa, Hidemichi Imamura, Masanori Terashima, Goro Shibukawa, Tadayuki Takagi, Yuta Takahashi, Ai Sato, Masaki Sato, Tsunehiko Ikeda, Rei Suzuki, Takuto Hikichi, Katsutoshi Obara, Hiromasa Ohira

Published in: International Journal of Clinical Oncology | Issue 3/2010

Abstract

A 58-year-old woman was admitted to our institute in June 2007 because of obstructive jaundice. A mass in the pancreatic head and multiple swollen lymph nodes surrounding the common hepatic artery were identified using computed tomography (CT). Subsequently, endoscopic ultrasonography-guided fine-needle aspiration biopsy (EUS-FNA) was done. Histopathologic results revealed anaplastic carcinoma of the pancreas. Using specimens obtained with EUS-FNA, chemosensitivity testing with adenosine triphosphate assay was performed. Testing indicated high chemosensitivity to paclitaxel (PTX). According to this result, chemotherapy using PTX was performed, and the primary lesion and lymph node metastases disappeared completely on CT. The patient has been doing well with no recurrence for 1 year and 11 months since initial chemotherapy.

Chen J, Baithun SI (1985) Morphological study of 391 cases of exocrine pancreatic carcinoma. J Pathol 146:17–29CrossRefPubMed

Ichikawa T, Federle MP, Ohba S et al (2000) Atypical exocrine and endocrine pancreatic tumors (anaplastic, small cell and giant cell types): CT and pathologic features in 14 patients. Abdom Imaging 25:409–419CrossRefPubMed

Paal E, Thompson LD, Frommelt RA et al (2001) A clinicopathologic and immunohistochemical study of 35 anaplastic carcinoma of the pancreas with a review of the literature. Ann Diagn Pathol 5:129–140CrossRefPubMed

Zamboni G, Capelli P, Pesci A et al (2000) Pancreatic head mass: what can be done? Classification: the pathological perspective. J Pancreas 1:77–84

Yamaguchi K, Nakamura K, Shimizu S et al (1998) Pleomorphic carcinoma of the pancreas: reappraisal of surgical resection. Am J Gastroenterol 93:1151–1155CrossRefPubMed

Furukawa T, Kubota T, Suto A et al (1991) Clinical usefulness of chemosensitivity testing using the MTT assay. J Surg Oncol 48:188–193CrossRefPubMed

Yamaue H, Tanimura H, Noguchi K et al (1992) Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cells using the MTT assay. Br J Cancer 66:794–799PubMed

Kawamura H, Ikeda K, Takiyama I et al (1997) The usefulness of the ATP assay with serum-free culture for chemosensitivity testing of gastrointestinal cancer. Eur J Cancer 33:960–966CrossRefPubMed

Vilmann P, Jacobsen GK, Henriksen FW et al (1992) Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease. Gastrointest Endosc 38:172–173CrossRefPubMed

10.

Wiersema MJ, Vilmann P, Giovannini M et al (1997) Endosonography-guided fine needle aspiration biopsy: diagnostic accuracy and complication assessment. Gastroenterology 112:1087–1095CrossRefPubMed

11.

Wakatsuki T, Irisawa A, Bhutani MS et al (2005) Comparative study of diagnostic value of cytologic sampling by endoscopic ultrasonography-guided fine-needle aspiration and that by endoscopic retrograde pancreatography for the management of pancreatic mass without biliary stricture. J Gastroenterol Hepatol 20:1707–1711CrossRefPubMed

12.

Chadha MK, LeVea C, Javle M et al (2004) Anaplastic pancreatic carcinoma. A case report and review of literature. J Pancreas 5:512–515

13.

Pan ZG, Wang B (2007) Anaplastic carcinoma of the pancreas associated with a mucinous cystic adenocarcinoma. A case report and review of the literature. J Pancreas 8:775–782

14.

Kim HA, Yom CK, Moon BI et al (2008) The use of an in vitro adenosine triphosphate-based chemotherapy response assay to predict chemotherapeutic response in breast cancer. Breast 17:19–26CrossRefPubMed

15.

Konecny G, Crohns C, Pegram M et al (2000) Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer. Gynecol Oncol 77:258–263CrossRefPubMed

16.

Moon YW, Choi SH, Kim YT et al (2007) Adenosine triphosphate-based chemotherapy response assay (ATP-CRA)-guided platinum-based 2-drug chemotherapy for unresectable nonsmall-cell lung cancer. Cancer 109:1829–1835CrossRefPubMed

17.

Yasuda H, Takada T, Wada K et al (1998) A new in vitro drug sensitivity test (collagen-gel droplet embedded-culture drug sensitivity test) in carcinomas of pancreas and biliary tract: possible clinical utility. J Hepatobiliary Pancreat Surg 5:261–268CrossRefPubMed

18.

Skubitz KM, Haddad PA (2005) Paclitaxel and pegylated-liposomal doxorubicine are both active in angiosarcoma. Cancer 104:361–366CrossRefPubMed

19.

Schlemmer M, Reichardt P, Verweij J et al (2008) Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 44:2433–2436CrossRefPubMed

20.

Tulpule A, Groopman J, Saville MW et al (2002) Multicenter trial of low dose paclitaxel in patients with advanced AIDS related Kaposi sarcoma. Cancer 95:147–154CrossRefPubMed

21.

Fardet L, Stoebner PE, Bachelez H et al (2006) Treatment with taxanes of refractory or life-threatening Kaposi sarcoma not associated with human immunodeficiency virus infection. Cancer 106:1785–1789CrossRefPubMed

22.

Toyoshima M, Akahira J, Matsunaga G et al (2004) Clinical experience with combination paclitaxel and carboplatine therapy for advanced or recurrent carcinosarcoma of the uterus. Gynecol Oncol 94:774–778CrossRefPubMed

23.

Pectasides D, Pectasides E, Papaxoinis G et al (2008) Combination chemotherapy with carboplatine, paclitaxel and pegylated liposomal doxorubicin for advanced or recurrent carcinosarcoma of the uterus: clinical experience of a single institution. Gynecol Oncol 110:299–303CrossRefPubMed

Title: Complete response of anaplastic pancreatic carcinoma to paclitaxel treatment selected by chemosensitivity testing
Authors: Takeru Wakatsuki
Atsushi Irisawa
Hidemichi Imamura
Masanori Terashima
Goro Shibukawa
Tadayuki Takagi
Yuta Takahashi
Ai Sato
Masaki Sato
Tsunehiko Ikeda
Rei Suzuki
Takuto Hikichi
Katsutoshi Obara
Hiromasa Ohira
Publication date: 01-06-2010
Publisher: Springer Japan
Published in: International Journal of Clinical Oncology / Issue 3/2010
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-010-0038-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2010

Comparison of combination chemotherapy with irinotecan and cisplatin regimen administered every 2 or 4 weeks in pretreated patients with unresectable or recurrent gastric cancer: retrospective analysis

Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science

Supraclavicular lymph node metastasis as the initial presentation of primary fallopian tube carcinoma

A case of rapidly growing pulmonary carcinosarcoma

Preoperative assessment of para-aortic lymph node metastasis in patients with pancreatic cancer

A pretreatment nomogram predicting recurrence- and progression-free survival for nonmuscle invasive bladder cancer in Japanese patients

Keynote webinar | Spotlight on antibody–drug conjugates in cancer